GRIFOLS

Grifols fully refinances all 2027 maturities following a significantly upsized €3bn Term Loan B

- ***Total equivalent amount of c. €3billion, reflecting strong investor demand globally and broad support from institutional investors***

- ***Upsizing both the USD and euro-denominated tranches, with the euro-denominated tranche upsized significantly to €1.25 billion from €500 million target, driven by robust market appetite. The USD tranche was upsized to $2.0 billion***

- ***Enhanced documentation and financial terms across both tranches, including margin reduction ratchets and an extension of maturities to seven years***

- ***Continued progress in the company's deleveraging roadmap and further optimization of its debt maturity profile***

- ***With the completion of the TLB, the significantly upsized €1.75 billion equivalent Revolving Credit Facility will also become effective, that was supported by a broad syndicate of leading international financial institutions, including BofA, JPMorgan, DNB, Santander, Citi, Commerzbank, Deutsche Bank, Goldman Sachs Bank Europe SE, HSBC, Helaba, UBS, ING and Nomura***

Barcelona, Spain, April 1, 2026 – Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a global healthcare company and leading producer of plasma-derived medicines, will successfully refinance its 2027 maturities, both Senior Secured Term Loan B (TLB) and Senior Secured Bonds, with a significantly upsized new Senior Secured TLB of c€3 billion with a seven year maturity and tighter pricing than at launch, strengthening its capital structure and reinforcing its strong positioning in the credit markets, despite the challenged market backdrop.

The transaction attracted strong institutional demand, allowing both USD and euro-denominated tranches to be upsized to c. €3billion equivalent in total, the latter upsized to €1.25 billion from an initial target of €500million.

The U.S. dollar TLB, to be issued by Grifols International Services USA Inc., was priced at SOFR + 250 with an OID of 99.25. The euro tranche was set at Euribor + 300 basis points with an OID of 99.75.

The proceeds will be used on or about the closing date of the transaction to refinance existing TLB maturities due in 2027 and fully repay €740 million of senior secured notes also maturing in 2027, supporting the simplification and extension of the company's debt maturity profile.

Upon the completion of the TLB, the significantly upsized Revolving Credit Facility ("RCF") of €1.75 billion equivalent will also become effective. The RCF was supported by a broad syndicate of leading international financial institutions, including BofA, JPMorgan, DNB, Santander, Citi, Commerzbank, Deutsche Bank, Goldman Sachs Bank Europe SE, HSBC, Helaba, UBS, ING, acting as Joint Lead Arrangers and Bookrunners and Nomura as co-manager.

Grifols has been advised by Osborne Clarke, Proskauer Rose LLP and Milbank LLP.

The company's credit ratings stand at B1 / BB- / BB- at the corporate level and Ba3 / BB- / BB+ for the facility, reflecting the evolution of its financial profile within the current execution phase of its strategic plan.

Rahul Srinivasan, CFO of Grifols, said: "Despite the tricky capital markets backdrop, the overwhelmingly positive response from TLB investors strongly validates both the highly attractive and highly defensive fundamentals of Grifols, facilitating an acceleration of our refinancing plans. We remain very focused on targeting lower cash interest expense and look forward to updating the market in due course."

About Grifols

Grifols is a global healthcare company founded in Barcelona in 1909 committed to improving the health and well-being of people around the world. A leader in essential plasma-derived medicines and transfusion medicine, the company develops, produces and provides innovative healthcare services and solutions in more than 110 countries.

Patient needs and Grifols' ever-growing knowledge of many chronic, rare and prevalent conditions, at times life-threatening, drive the company's innovation in both plasma and other biopharmaceuticals to enhance quality of life. Grifols is focused on treating conditions across four main therapeutic areas: immunology, infectious diseases, pulmonology and critical care.

A pioneer in the plasma industry, Grifols continues to grow its network of donation centers, the world's largest with close to 400 across North America, Europe, Africa and the Middle East, and China.

As a recognized leader in transfusion medicine, Grifols offers a comprehensive portfolio of solutions designed to enhance safety from donation to transfusion, in addition to clinical diagnostic technologies. It provides high-quality biological supplies for life-science research, clinical trials and for manufacturing pharmaceutical and diagnostic products. The company also supplies tools, information and services that enable hospitals, pharmacies and healthcare professionals to efficiently deliver expert medical care.

Grifols, with more than 23,800 employees in more than 30 countries and regions, is committed to a sustainable business model that sets the standard for continuous innovation, quality, safety and ethical leadership.

The company's class A shares are listed on the Spanish Stock Exchange, where they are part of the IBEX-35 (MCE:GRF). Grifols non- voting class B shares are listed on the Mercado Continuo (MCE:GRF.P) and on the U.S. NASDAQ through ADRs (NASDAQ:GRFS).

For more information about Grifols, please visit www.grifols.com

MEDIA CONTACTS:

Grifols Press Office
media@grifols.com
Tel. +34 93 571 00 02

INVESTORS:

Investor Relations & Sustainability
inversores@grifols.com - investors@grifols.com
sostenibilidad@grifols.com – sustainability@grifols.com
Tel. +34 93 571 02 21

LEGAL DISCLAIMER

The facts and figures contained in this report that do not refer to historical data are ‘projections and future hypotheses’. Words and expressions such as ‘believe’, ‘expect’, ‘anticipate’, ‘predict’, ‘hope’, ‘intend’, ‘should’, ‘will try to achieve’, ‘is estimated’, ‘future’ and similar expressions, insofar as they refer to the Grifols group, are used to identify future projections and hypotheses. These expressions reflect the assumptions, hypotheses, expectations and predictions of the management team at the time of writing this report, and these are subject to a series of factors that mean that the real results may be materially different. The future results of the Grifols group could be affected by events related to its own activities, such as shortages of supplies of raw materials for the manufacture of its products, the appearance on the market of competing products, or changes in the regulatory framework of the markets in which it operates, among others. At the date of preparation of this report, the Grifols group has adopted the necessary measures to mitigate the potential impact of these events. Grifols, S.A. assumes no obligation to publicly report, revise or update the projections or future hypotheses to adapt them to facts or circumstances after the date of writing of this report, except when expressly required by applicable legislation. This document does not constitute an offer or invitation to purchase or subscribe shares in accordance with the provisions of Law 6/2023, of 17 March, on the Securities Markets and Investment Services, and any regulations implementing said legislation. Furthermore, this document does not constitute an offer to purchase, sell or exchange, or a solicitation of an offer to purchase, sell or exchange any securities, or a solicitation of any vote or approval in any other jurisdiction. The information contained in this document has not been verified or revised by the external auditors of the Grifols group.